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ABSTRACT
Appropriate control of the chromosome end-
replicating enzyme telomerase is crucial for main-
taining telomere length and genomic stability. The
essential telomeric DNA-binding protein Cdc13p
both positively and negatively regulates telomere
length in budding yeast. Here we test the effect of
purified Cdc13p on telomerase action in vitro.
We show that the full-length protein and its DNA-
binding domain (DBD) inhibit primer extension by
telomerase. This inhibition occurs by competitive
blocking of telomerase access to DNA. To further
understand the requirements for productive telo-
merase 3’-end access when Cdc13p or the DBD
is bound to a telomerase substrate, we constrained
protein binding at various distances from the 3’-end
on two sets of increasingly longer oligonucleotides.
We find that Cdc13p inhibits the action of telomer-
ase through three distinct biochemical modes,
including inhibiting telomerase even when a signifi-
cant tail is available, representing a novel ‘action
at a distance’ inhibitory activity. Thus, while yeast
Cdc13p exhibits the same general activity as
human POT1, providing an off switch for telomerase
when bound near the 3’-end, there are significant
mechanistic differences in the ways telomere end-
binding proteins inhibit telomerase action.
INTRODUCTION
In 1985, a novel enzyme was identiﬁed in ciliates that adds
repeated DNA sequence to telomeric oligonucleotides (1).
This enzyme, telomerase, is a reverse transcriptase that
iteratively adds species-speciﬁc, GT-rich, DNA repeats
to the 30 ends of chromosomes. Telomerase has since
been identiﬁed in a wide range of eukaryotic organisms,
including humans, where it plays a prominent role in
cancer and a growing number of other diseases (2).
Telomerase is a ribonucleoprotein complex. In the yeast
Saccharomyces cerevisiae, the core enzyme consists of the
Est2p reverse transcriptase (or TERT) subunit and an
1157-nt RNA, TLC1 (3–7). In addition to the catalytic
subunit, the yeast telomerase holoenzyme also includes
the Est3 protein, and proteins that probably directly inter-
act with the ﬂexible RNA scaﬀold, including Est1p, the
Ku DNA repair heterodimer, and the Sm7 complex, also
involved in snRNA maturation (8–11). In vitro, whether
puriﬁed from yeast cells or reconstituted in a heterologous
system, yeast telomerase synthesizes predominantly a
single DNA repeat, after which it remains stably asso-
ciated with the ssDNA product (5,12). However, in vivo,
telomerase can add as little as a few to hundreds of nucleo-
tides to a single telomere in one cell cycle (13), suggesting
that additional telomere-associated proteins may modu-
late activity.
Telomere length homeostasis involves the coordination
of telomere lengthening and shortening processes.
Although the complete mechanism of telomere length reg-
ulation remains to be elucidated, several telomere-
associated proteins have been implicated in the process.
The observation that targeting the C-terminus of Rap1p
to telomeres leads to telomere shortening, and that this is
proportional to the number of molecules at a given telo-
mere, led to the ‘protein-counting model’ of telomere
length regulation by Rap1p (14). Thus, double-strand
DNA-binding factors play a role in length regulation.
Additionally, the abundance of limiting telomerase com-
ponents also appears to provide another level of regula-
tion. There are only  29 copies of the TLC1 RNA per
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abundance in a TLC1/tlc1 heterozygote leads to short
telomeres (15). This ﬁnding complemented those from
mammalian studies (16–19) that had also suggested that
telomerase activity can be regulated by the number of
active complexes. The function of the yeast ATM kinase
homolog, Tel1p, is important for proper telomere length
maintenance and is required for repeat addition processiv-
ity in vivo (20–22), implicating phosphorylation as critical
to telomere length regulation. It has also been proposed
that telomeres exist in either an extendible or non-extend-
ible state (13,23), which dictates whether or not telomerase
can access a particular telomere end. Recent studies show
that the extendible state tends to exist at the chromosome
ends with the shortest telomeres, where telomerase is
relatively enriched (24,25). Despite the many pathways
involved in regulating telomere length, control of telomer-
ase activity by modulating its access to chromosome ends
is one of the most fundamentally important.
The essential Cdc13 protein binds to the 30 telomere
overhangs through its structurally and biochemically char-
acterized ssDNA-binding domain (DBD) (26–30). Cdc13p
is a chromosome end-capping protein, preventing the
CA-rich strand of the telomere from undergoing unregu-
lated nucleolytic degradation (31). In addition, Cdc13p
regulates telomere elongation through recruitment of tel-
omerase via its Est1p subunit (32). Recruitment is abol-
ished in the cdc13-2
est mutant, which displays shortened
telomeres, similar to those of a telomerase-defective strain
(7). Cdc13p may also prevent runaway elongation by tel-
omerase, since yeast expressing the cdc13-5 allele, which
lacks the C-terminus, exhibit elongated telomeres and long
G-strand overhangs (33). Cdc13p is enriched at telomeres
during S-phase (24,25), providing additional support for
its role in telomere length regulation.
Telomeric ssDNA-binding protein complexes are
known to regulate telomerase activity. It was recently
shown that the human single-stranded telomere binding
protein POT1 (hPOT1) inhibits telomerase activity
in vitro on human telomere substrates (34,35). hPOT1
exerts its inhibitory eﬀect when bound within six nucleo-
tides of the 30-end of a ssDNA oligonucleotide substrate
(35). Both full-length protein and the DBD of hPOT1
display identical telomerase inhibitory activity, and
DNA-binding activity is required for inhibition (34,35).
Telomerase activity is fully restored even in the presence
of full-length hPOT1 or its DBD, if there is at least a 6-nt
tail beyond the hPOT1-binding site. This suggests that
the relative positioning of hPOT1 along the 30 telomere
overhangs can serve as a binary switch for telomerase-
accessibility (35). More recent evidence suggests that
hPOT1 regulates telomerase in conjunction with a
second shelterin component, TPP1. When both hPOT1
and TPP1 are prebound onto a telomeric oligonucleotide
substrate, the human telomerase core enzyme displays
enhanced processivity (36). While these data suggest a
potential telomerase regulatory role for hPOT1, how this
is manifested in vivo is not yet understood. Manipulation
of hPOT1 by overexpression (37–39) or RNAi suppression
of hPOT1 (40–43) leads to a variety of phenotypes, includ-
ing telomere elongation, 30 tail structure changes and
various DNA damage responses. The complexity of the
in vivo data does not provide a clear mechanism for how
hPOT1 might regulate telomerase activity, potentially due
to indirect eﬀects associated with the concomitant disrup-
tion of the large shelterin complex at telomeres upon
manipulation of hPOT1 (44,45). In contrast, understand-
ing of the role played by budding yeast Cdc13p in telo-
mere length regulation is somewhat clearer, due to the
availability of separation-of-function and temperature-
sensitive alleles (32).
As a starting point for evaluating the regulation of tel-
omerase by the host of factors identiﬁed through genetic
analysis in S. cerevisiae, it is important to know the extent
to which Cdc13p binding to telomeric DNA aﬀects its
ability to serve as a telomerase substrate. Until recently,
such studies were complicated by the inability to reconsti-
tute the yeast telomerase core enzyme in vitro and the
limitations associated with using immunopuriﬁed telomer-
ase from yeast extracts. The discovery that a miniaturized
yeast telomerase RNA component provides reconstituted
activity with yeast TERT when coexpressed in rabbit reti-
culocyte lysates (5) provides immunopuriﬁed core enzyme
to directly examine the role of telomere end-binding pro-
teins in the regulation of telomere length by telomerase.
We show that, unlike hPOT1, Cdc13p inhibits telomerase
activity on substrates that have substantial 30 overhangs.
This inhibitory activity is observed for both the DBD of
Cdc13p and the full-length protein, although we ﬁnd dif-
ferences between how the DBD and Cdc13p inhibit telo-
merase activity on speciﬁc substrates. We propose that
three mechanisms for yeast telomerase inhibition by
Cdc13p have a fundamental role in deﬁning the non-
extendible state of yeast telomeres.
MATERIALS AND METHODS
Cdc13pand Cdc13(DBD) expression andpurification
Full-length Cdc13p was expressed using baculovirus in Sf9
cells and puriﬁed as previously described (27,32), with the
following modiﬁcations. Brieﬂy, baculovirus-infected cells
were homogenized and Cdc13p was puriﬁed to >90%
homogeneity using Ni-aﬃnity chromatography (GE
Healthcare). Active concentrations of Cdc13p were deter-
mined by electrophoretic mobility shift assay (EMSA),
and deﬁned as the concentration of Cdc13p required to
fully shift 100nM GTGTGGGTGTG (TEL) probe, which
is >100-fold above the measured Kd.
Cdc13(DBD) constructs were overexpressed and puri-
ﬁed as described previously, with minor modiﬁcations
(27). Glycerol and detergents were removed from the
lysis buﬀer, and lysis was carried out by sonication.
The protein domain was puriﬁed using ion-exchange,
Ni-aﬃnity and size-exclusion chromatography (GE
Healthcare). Filter binding assays were employed to deter-
mine the active concentration of DBD protein for all sub-
sequent assays. Active concentration was deﬁned as the
concentration of protein required to fully bind the stan-
dard TEL oligonucleotide at a concentration of 200nM,
well above the measured Kd of the DBD TEL interaction.
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Reconstituted yeast telomerase was synthesized in rabbit
reticulocyte lysates (Promega), as described (5), using plas-
mids encoding the Mini-T(500) RNA and ProA-tagged
Est2p. At the ﬁnal step of telomerase immunopuriﬁcation,
IgG Sepharose beads were resuspended 1:3 (v/v) with
10mM Tris (pH 8), 1mM MgCl2 and 30% (v/v) glycerol.
Telomerase from yeast extracts had been isolated pre-
viously from cells overexpressing both TLC1 RNA and
ProA-tagged Est2p (46). Unless otherwise indicated, all
telomerase assays were performed as reported previously
(5), except at 278C for 10min with ﬁnal substrate concen-
tration at 0.3mM. When included, DBD or Cdc13p were
preincubated with primer DNA for at least 15min on ice
prior to adding telomerase and radioactive [a
32P]-dGTP.
All oligonucleotide substrates were commercially PAGE
or reverse-phase HPLC-puriﬁed. Markers for +1 telomer-
ase products were made essentially as described (5).
Telomerase signal (detected by a GE Typhoon Trio phos-
phorimager) was quantiﬁed by using Imagequant TL soft-
ware (GE Healthcare) to sum the signal from the reaction
products (typically +1 through +7 bands) and normalize
it to the internal loading and recovery control. To deter-
mine the stoichiometry of DBD required for telomerase
inhibition, we determined the amount of protein required
to inhibit 78% (on average) of the telomerase signal from
six completely independent protein preparations. It
required 0.81 0.64 (mean SD) equivalents of protein
to achieve this level of inhibition. The high variability is
likely caused by batch-to-batch diﬀerences in the quanti-
tation of DBD protein preparations, as the extent of inhi-
bition was highly reproducible for a given preparation.
Binding assays
Filter-binding assays were used to determine equilibrium
binding constants for interactions with Cdc13(DBD).
The concentration of DNA used for all experiments
was 50pM and the protein concentrations were varied
 100-fold above and below the measured Kd. Oligonu-
cleotides were 50-end labeled as described (27). All ﬁlter-
binding reactions were carried out in high-salt binding
buﬀer (28). The salt-dependence of the Cdc13(DBD) inter-
action has been previously shown to be log-linear (28),
hence the high-salt buﬀer was used to reduce the aﬃnity
of the interactions to the nM range to facilitate more
accurate measurements. A Schleiser & Schuell minifold
vacuum manifold dot blot apparatus was used, employing
a two-ﬁlter method (47) consisting of a nitrocellulose ﬁlter
(GE Infrastructure Water & Process Technologies) to cap-
ture the protein and bound DNA, and a HyBond (XL)
ﬁlter (Amersham Biosciences) to capture free DNA. Mem-
branes were washed twice with 90ml of binding buﬀer
(without BSA) prior to the addition of 30ml of each reac-
tion mixture. Membranes were then washed three times
with 90ml of binding buﬀer (without BSA) then dried
and exposed to phosphorimager plates. ImageQuant
(GE) software was used to quantify the DNA signal
from each membrane ﬁlter. The data were normalized to
obtain fraction bound and ﬁt to a two-state binding model
as described (29). The reported and relative Kd values are
the average of triplicate measurements independently
repeated three times, reported with standard error.
Equilibrium binding constants for the interactions of
telomeric oligonucleotides and Cdc13p were measured
using EMSAs. Protein concentrations were varied from
0.3pM to 3mM with 50-end labeled DNA concentration
constant at 20pM. Reactions and gel conditions were as
described previously (27,32,48), except that binding
was allowed to equilibrate for 30min. Binding constants
were measured by ﬁtting the data to the same two-state
binding model as previously described (29). The apparent
and relative Kd values reported are averages of triplicate
experiments with standard errors.
Snake venom phosphodiesterase exonuclease assays
Experiments were performed as previously described (35),
with minor modiﬁcations. Binding was performed on ice
and 50-end labeled DNA concentrations were lowered
to 0.3mM due to higher aﬃnity of the Cdc13 DNA inter-
actions, and to match the conditions of telomerase exten-
sion assays. For the experiment shown in Figure 4a,
the protein DNA complex was pre-formed at a 10:1
molar ratio prior to the addition of Snake venom phos-
phodiesterase (SVP) (Worthington Biochemical
Corporation) to the reactions, whereas for experiments
in Figure 4b, the protein concentration was titrated
onto each oligonucleotide (see ﬁgure legend for ratio of
protein:DNA for each lane). The reaction was incubated
at 308C for the indicated time in Figure 4a, and for
12min in Figure 4b, then stopped with the addition of
50mMN a 2EDTA. Samples were run on 20% denaturing
polyacrylamide gels, (1  TBE, 7M urea) and these were
dried and exposed to phosphorimager plates for
visualization.
Coordinated nuclease/telomerase assays
Varying concentrations of Cdc13p or its DBD, diluted
with their storage buﬀers, were incubated with the indi-
cated primer diluted in telomerase reaction buﬀer (50mM
NaCl, 40mM Tris (pH 8), 5% (v/v) glycerol, 2.5mM
MgCl2, 0.5mM spermidine, 0.5mM DTT). A trace
amount of polynucleotide kinase 50-labeled primer was
also included (ﬁnal concentration of 0.5nM and
1500cpm/ml). After binding on ice for 15min, telomerase
reaction components were added, except telomerase and
[a
32P]-dGTP. The reactions where then split into two
tubes and one was used for telomerase assay while mock
treatment with telomerase storage buﬀer was added to the
other, which was then incubated with SVP at 278C for
12min. SVP digestion products were subsequently run
on 12% sequencing-sized denaturing polyacrylamide
gels, (1  TBE, 7M urea) which were then dried and
exposed to phosphorimager plates for visualization.
RESULTS
The DNA bindingdomain ofCdc13p inhibits telomerase
We began by analyzing the eﬀect of the DBD of Cdc13p
(Figure 1a) on telomerase activity, since this protein
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ized (26–28,30). A standard 15-nt yeast telomeric DNA
primer (12,46,49–52), referred to here as TP1, was tested
ﬁrst. This oligonucleotide ends in –GGG, constraining
base pairing with yeast telomerase RNA to the unique
occurrence of CCC in the template (Figure 1b, bottom).
Therefore, yeast telomerase adds up to 7nt, as has been
shown previously for both the wild-type enzyme puriﬁed
from yeast extracts (6,53) and the reconstituted enzyme
with the miniaturized TLC1 RNA, Mini-T(500) (5).
Both the reconstituted and the yeast-expressed telomerase
were potently inhibited when the DBD of Cdc13p was
preincubated with TP1 (Figure 1b).
Telomerase action was completely inhibited when the
concentration of Cdc13(DBD) was approximately equal
to that of the DNA primer (Figure 1c). In six telomerase
experiments each performed with a diﬀerent DBD protein
preparation, the ratio of DBD:DNA required for inhibi-
tion was 1.0 0.8 (mean SD). If Cdc13(DBD) was heat-
denatured, inhibition was completely abolished (Figure 1c,
lane 10). We also tested importance of the order of addi-
tion by adding Cdc13(DBD) after telomerase and primer
had been pre-incubated for 10min. In this case, inhibition
was intermediate (Figure 1c, lane 12), probably because
the oligonucleotide substrate is competed away by the
relatively fast and tight binding of the Cdc13(DBD)
(27). Lastly, we show that the DNA synthesis observed
was clearly due to telomerase activity since it was abol-
ished by RNase and also required dTTP, the ﬁrst nucleo-
tide predicted to be added by the TLC1 template
(Figure 1c, lanes 11 and 13).
If Cdc13(DBD) inhibits telomerase by blocking its
access to the DNA substrate, rather than, for example,
binding to telomerase, then a mutant DBD with a speciﬁc
reduction in DNA association should not inhibit eﬀec-
tively. Y522A reduces DNA-binding by the Cdc13(DBD)
650-fold (28). When tested for its eﬀect on telomerase
action, DBD (Y522A) did not inhibit (Figure 1d).
Lack of inhibition by the Y522A Cdc13(DBD) mutant is
not due to inactive protein. At high concentrations, DBD
(Y522A) did bind DNA by ﬁlter-binding and weak telo-
merase inhibition was observed when 10-fold more protein
Figure 1. The DBD of Cdc13p inhibits yeast telomerase. (a) Schematic
of Cdc13p. The DBD resides near the C-terminus of the protein (amino
acids 497–694). Puriﬁed Cdc13(DBD) (24.7kDa with the His6 tag) is
shown on a Coomassie-stained gel (right). E252, residue required for
binding Est1p to recruit telomerase (32). Y522, amino acid important
for high-aﬃnity DNA-binding (27). (b) DBD inhibits telomerase
in vitro. Cdc13(DBD) was incubated with the 15-nt primer TP1 and
then telomerase was added along with deoxynucleotides A, C, T and
[a-
32P]-dGTP. M, reconstituted mini-telomerase. Y
WT, telomerase from
extracts of yeast overexpressing ProA-Est2p and 1157-nt TLC1. The
+1 and +7 telomerase extension products are indicated with ﬁlled and
open triangles, respectively. Primer TP1 aligns with telomerase RNA as
shown; arrow denotes template-directed DNA synthesis up to the
boundary element (dotted line). Primer concentration was 0.3mM.
Reactions contained 0.6mM Cdc13(DBD) (+) or its storage buﬀer
( ). Gray lines show instances of GxGT, the essential 50 binding por-
tion of the Cdc13(DBD) binding consensus. (c) Cdc13(DBD) inhibits
telomerase when present at a concentration similar to TP1 primer.
Reaction conditions were essentially the same as when using reconsti-
tuted mini-telomerase in b. Water and Cdc13(DBD) storage buﬀer
controls are shown in lanes 1 and 2, respectively. Lanes 3–9, increasing
amounts of Cdc13(DBD) were incubated with DNA prior to adding
telomerase. Lane 10, boiled (denatured) Cdc13(DBD). Lane 11, telo-
merase incubated for 10min at 378C with RNase A to degrade Mini-T
RNA. Lane 12, 0.9mM Cdc13(DBD) added after primer and telomer-
ase were incubated on ice for 10min. Lane 13, The ﬁrst nucleotide
encoded by the RNA template, dTTP (b), was omitted. LC, loading
and recovery control: TP1 primer labeled with
32P at its 50-end, which
increases electrophoretic migration from increased negative charge. (d)
DNA-binding-defective point mutant of Cdc13(DBD) does not inhibit
telomerase in vitro. Standard deviation from three independent experi-
ments is shown. Experiments were performed as in b and quantitated
as described in Materials and Methods section. Primer concentration
was 0.3mM.
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required for telomerase inhibition by Cdc13(DBD).
Full-length Cdc13p inhibits telomerase similarly tothe DBD
The 198-residue DBD of Cdc13p inhibits telomerase, but
the full-length protein is much larger (924 amino acids)
and contains several other domains that also participate
in telomere maintenance and length regulation (54, 32,
33). Therefore, we puriﬁed recombinant full-length
Cdc13p to high homogeneity (Figure 2a) (32) and tested
its eﬀect on telomerase.
When we preincubated Cdc13p with the telomeric
primer TP1 (Figure 1b) and then added telomerase, we
observed telomerase inhibition very similar to that with
the DBD (Figure 2b): the inhibition was, within error,
reproducibly stoichiometric with respect to primer and
was abolished by heat-denaturing Cdc13p. Cdc13p also
inhibited telomerase isolated from yeast overexpressing
the core enzyme components Est2p and the full-length
TLC1 RNA (Figure 2c). Furthermore, the amount of
DBD and Cdc13p required for inhibition scaled with
primer concentration (data not shown). Thus, full-length
Cdc13p and its DNA binding domain both inhibit telo-
merase by binding to the DNA substrate, leading us to
favor a model where Cdc13p prevents productive telomer-
ase access.
Validation ofa system tocontrol theDNA-binding register
ofCdc13(DBD)
We set out to determine if addition of a free 30 DNA
tail would restore telomerase activity to a Cdc13(DBD)-
or Cdc13p-bound oligonucleotide. Binding of the
Cdc13(DBD) to telomeric sequence occurs through a mini-
mal consensus binding site containing a GxGT motif at
the 50 end of an otherwise GT-rich 11-mer sequence (29).
Thus, longer deoxyoligonucleotides representing degener-
ate sequence of yeast telomeres typically contain multiple
consensus Cdc13(DBD) binding sites. This degeneracy of
yeast telomeres and the minimal GxGT DBD-binding
motif complicate determining the ssDNA tail beyond
bound Cdc13(DBD) needed for telomerase action, since
simply adding telomeric sequence to a minimal DBD-bind-
ing oligonucleotide creates multiple overlapping protein-
binding registers (see next section). Therefore, to test
how close to the DNA 30-end Cdc13(DBD) must be
in order to inhibit telomerase action, we designed four
potential telomerase substrates predicted to restrict DBD
binding to the single 11-nt register at the 50-end, allowing
for a deﬁned protruding 30 tail. Based on prior knowledge
of Cdc13(DBD) binding to DNA, our designed sequences
are expected to have only one high-aﬃnity consensus site
(Figure 3a) even if lengthened at the 30-end by  9nt. As
expected from the lack of perfect sequence-complementar-
ity to telomerase RNA, these oligonucleotides were subop-
timal telomerase substrates, but their ability to serve as
telomerase primers was improved by adding –GG or –
TGG to their 30-ends, which increases pairing to TLC1
(Supplementary Figure 1 and data not shown). Because
TEL
  permitted the most telomerase activity, we used
this sequence as the basis for design of primer substrates
with 30 tails of increasing length.
As anticipated based on its binding consensus,
Cdc13(DBD) bound to TEL
 , although 220-fold more
weakly than to TEL (Figure 3a and Table 1). Some recov-
ery of binding aﬃnity was observed when additional Gs
were appended to the 30-end of TEL
 ; the mechanism of
this recovery is currently under investigation. Given the
3pMKd of Cdc13(DBD) for TEL in low salt (27), binding
to the TEL-derivative, TEL
 , is predicted to be sub-
nanomolar under the conditions of our telomerase
experiments, and thus Cdc13(DBD) would bind all of
the primer (300nM) when present at equimolar con-
centration (see Table 1; n.b. higher Kd values shown
in Table 1 are from experiments done at 750mM KCl
to facilitate quantitative analysis (28) given the very
tight interaction).
Figure 2. Full-length Cdc13p inhibits telomerase. (a) Coomassie-stained SDS–PAGE gel of puriﬁed Cdc13p (108kDa with His6 tag). (b) Cdc13p
inhibits reconstituted yeast telomerase activity in a concentration dependent manner on TP1 primer. See Figure 1b for alignment of primer with
telomerase RNA. Water, Cdc13p storage buﬀer and boiled Cdc13p negative controls are shown. Relative activity is listed below lanes. (c) Cdc13p (C)
and its DBD (D) inhibit wild-type telomerase (Y
WT) puriﬁed from yeast extracts similarly to miniaturized reconstituted telomerase (M). Experimental
conditions were the same as in Figure 1b.
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  oligo-
nucleotide (Figure 3b and Table 2). As reported pre-
viously, Cdc13p binds telomeric DNA with  100-fold
weaker aﬃnity relative to Cdc13(DBD) (27), a trend
observed throughout the series of oligonucleotides used
in this study (Tables 1 and 2). Cdc13p has the same
consensus binding sequence as its DBD; however, it exhi-
bits higher tolerance for changes at speciﬁc positions
within the canonical oligonucleotide GTGTGGGTGTG
(Tables 1, 2 and J.N.R. and D.S.W. unpublished results).
The fact that Cdc13p has a similar binding consensus to
DBD provides additional evidence that the major DNA-
binding activity originates from the DBD (residues
497–694; Figure 1a) (27,48). Binding of Cdc13p to TEL
 
is consistent with these biochemical features identiﬁed on
fully telomeric substrates. Cdc13p bound more weakly to
TEL
  than to TEL, although it was less impacted by the
sequence changes (26-fold versus 220-fold). This suggests
that there is a role for other portions of the protein in
modulating Cdc13p interactions with DNA.
We next addressed whether the TEL
  sequence indeed
constrains protein binding to the 50 region of the primer
DNA, even when multiple telomeric nucleotides are added
at its 30-end. We used a 30-speciﬁc exonuclease, snake
venom phosphodiesterase (SVP) (35,55), to determine
the extent of protection by Cdc13p or DBD. First,
TEL
 –GTGGG and a control oligonucleotide containing
a tract of adenosines as a 30 tail, TEL–a10, were incubated
Figure 3. Design of a single GxGT-containing mutant sequence, TEL
 ,
that still permits binding by Cdc13(DBD) and full-length Cdc13p. (a)
Like TEL, mutant TEL
  binds to Cdc13(DBD), although with reduced
aﬃnity (see also Table 1). Left, schematic of mutations (bold) engi-
neered into the canonical 11-nt Cdc13(DBD) binding site, TEL, to
generate TEL
 , which has only one remaining GxGT consensus site
(indicated by gray bars). Right, representative membranes and quanti-
ﬁed data from dot blot ﬁlter-binding experiments to determine the
aﬃnity of Cdc13(DBD) for the TEL and TEL
  sequences. Note that
ﬁlter binding was performed under high-salt (750mM KCl) conditions
(28) to reduce binding of Cdc13(DBD) to TEL, which is otherwise so
tight (Kd=3pM at 75mM monovalent salt) that it is technically diﬃ-
cult to measure accurately. (b) Like DBD, full-length Cdc13p also binds
TEL
  but with reduced aﬃnity relative to TEL. A representative gel-
shift using 50-end labeled TEL
  is shown (top). Cdc13p TEL
 , the pro-
tein–DNA complex in the nondenaturing gel; free probe is the unbound
50-end labeled oligonucleotide. A graphical representation of the quan-
tiﬁed gel shift signal is shown (bottom). All curves were ﬁtted to a two-
state binding model, as described in the Materials and Methods section.
Table 1. Binding of TEL and TEL
 -based sequences to Cdc13(DBD)
Oligonucleotide Sequence Kd,app
a
(nM)
Relative
Kd
b
TEL GTGTGGGTGTG 2.8 0.6  
TEL
  GTGTcTGTcTG 620 120 220
TEL
 -a10 GTGTcTGTcTGaaaaaaaaaa 380 57 140
TEL
 -GG GTGTcTGTcTGGG 120 19 43
TEL
 -GGG GTGTcTGTcTGGGG 33 5.7 12
TEL
 -GTGGG GTGTcTGTcTGGTGGG 11 1.3 4
TEL
 -GTGTGGG GTGTcTGTcTGGTGTGGG 24 4.3 8.6
TEL
 -GTGTGTGGG GTGTcTGTcTGGTGTGTGGG 13 1.8 4.6
aBinding experiments were performed in 750mM KCl to attenuate the
picomolar aﬃnity of Cdc13(DBD) for TEL sequence to the nanomolar
range. Kd values shown are averages of at least three independent
apparent Kd measurements standard error.
bKd values presented are relative to the Kd of the TEL oligonucleotide.
Table 2. Cdc13p binding to non-cognate telomeric sequences shows
similar binding trends to the Cdc13(DBD) with increased tolerance to
non-telomeric nucleotides
Oligonucleotide Sequence Kd,app
a
(nM)
Relative
Kd
b
TEL GTGTGGGTGTG 0.43 0.17  
TEL
  GTGTcTGTcTG 11 3.8 26
TEL
 -a10 GTGTcTGTcTGaaaaaaaaaa 7.4 2.4 17
TEL
 -GG GTGTcTGTcTGGG 0.81 0.03 1.9
TEL
 -GGG GTGTcTGTcTGGGG 2.2 0.7 5.1
TEL
 -GTGGG GTGTcTGTcTGGTGGG 3.1 0.8 7.2
TEL
 -GTGTGGG GTGTcTGTcTGGTGTGGG 0.81 0.15 1.9
TEL
 -GTGTGTGGG GTGTcTGTcTGGTGTGTGGG 0.3 0.3 0.83
aKd values are reported as apparent Kd values and are averages of at
least three independent measurements standard error.
bRelative Kd values presented are relative to the Kd of the TEL
oligonucleotide.
Nucleic Acids Research,2009, Vol. 37,No. 2 359with Cdc13p and then digested by SVP in a 60-min time
course—the 50 nucleotides were protected in a Cdc13p-
dependent manner (Figure 4a). Thus, TEL was protected
as expected by Cdc13p after the  a10 30 tail was trimmed
oﬀ by SVP. This assay shows that Cdc13p was speciﬁcally
targeted to the engineered TEL
  sequence when ﬁve telo-
meric 30 nucleotides were appended, because after 10min
of exonuclease action the 50 12 nucleotides remained pro-
tected (Figure 4a). The transience of the TEL
  protection
probably originates from a relatively quick oﬀ-rate of the
full-length protein (27) for the mutant TEL
  consensus.
These results show that  10-min incubations with SVP
are optimal for studying Cdc13p TEL
  interactions.
To compare the binding position of Cdc13(DBD)
with that of full-length Cdc13p on TEL
 -based
oligonucleotides, we performed titrations from substoi-
chiometric protein levels to >2:1 protein-to-DNA
ratios. For TEL
 –GTGGG, the DBD and Cdc13p
showed indistinguishable patterns of SVP 30 nuclease pro-
tection of the TEL
  sequence (Figure 4b, left). However,
when we titrated these proteins on TEL
 -based primers
with longer 30 tails, such as TEL
 –GTGTGTGGG, we
observed protection at the 30-end. At low concentrations,
Cdc13(DBD) bound the TEL
  sequence at the 50-end and,
at higher concentrations, protected a 30 site. Cdc13p,
on the other hand, protected the 30-end of TEL
 –
GTGTGTGGG from SVP digestion even at substoichio-
metric levels, suggesting that the 9-mer tail binds Cdc13p
more tightly than TEL
  (Figure 4b, right). Thus, Cdc13p
and its DBD can be directed to the 50-end of TEL
  in the
Figure 4. SVP 30 exonuclease assays show that Cdc13p and its DBD both bind speciﬁcally to the 50 region of TEL
 –GTGGG, but diﬀer in binding
site preference on longer oligonucleotides. (a) SVP digestion time course experiments show that Cdc13p DNA-binding protects the TEL region of a
TEL–a10 control and 11-nt TEL
  sequence in TEL
 –GTGGG. Time of incubation with SVP is indicated above. Correspondence of portions of the
gel to relative position in the oligonucleotide sequence is indicated to the left: TEL or TEL
  with tails of 10 adenosines or –GTGGG, a telomeric
sequence complementary to a unique portion of the telomerase template. Totally digested represents the signal resulting from complete SVP digestion
of the 50-end labeled oligonucleotides. (b) Cdc13(DBD) and full length protein bind to TEL
  when a GTGGG extension is appended, but Cdc13p
selectively binds to a GTGTGTGGG extension. The molar ratios of DBD:DNA (lanes 3–9 and 18–24) are 0.5:1, 1:1, 1.5:1, 2:1, 3:1, 5:1, and
10:1. Molar ratios of Cdc13p:DNA (lanes 12–15 and 27–30) are 0.5:1, 1:1, 1.5:1, and 2:1.
360 Nucleic Acids Research, 2009, Vol. 37, No. 2context of a telomeric substrate with short tails. However,
longer telomeric tails create additional alternate binding
sites for Cdc13p and the DBD, thus restricting the tail
length that can be examined using this approach.
Coordinated nucleaseprotection and telomerase
experiments unveil modesof Cdc13p inhibition
We recognized that the most direct assessment of end
structure and its correlation with telomerase activity
could be achieved if the telomerase and exonuclease
assays were performed on the same Cdc13p DNA com-
plex. Therefore, we developed a coordinated assay that
essentially eliminates variability that exists when exonu-
clease and telomerase assays are performed separately
on independently formed protein DNA complexes. This
was achieved by doing the two assays in parallel: each
particular Cdc13p DNA binding reaction is split and
one portion is incubated with telomerase and the other
with SVP 30 nuclease (Figure 5a). We refer to this techni-
que as the CoNuTe (coordinated nuclease/telomerase)
assay. A trace amount of 50 32P-labeled primer is included
in the initial binding reaction to allow subsequent moni-
toring of protection by DBD/Cdc13p from SVP. It also
serves as a loading control for telomerase assays. Tracer
oligonucleotide is not detectably extended since it is at
least 600-fold less abundant than the cold primer.
We applied the CoNuTe assay to a series of TEL
 -based
telomeric DNA substrates with diﬀering lengths
(Figure 5b). As observed in the SVP digestion assay
alone (Figure 4), SVP analysis of the protein DNA com-
plex used in the telomerase assay showed that, at approxi-
mately stoichiometric protein:DNA concentrations,
Cdc13(DBD) was indeed bound to the 50 TEL
  region,
as designed. With a telomeric tail of –TGTGGG or
longer, protection of the 30-end of the oligonucleotide
occurred when Cdc13(DBD) was present at high concen-
tration (Figure 5b, lanes 29 and 37), suggesting that
Cdc13(DBD) binds these long DNA tails secondarily to
the TEL
  sequence. This is consistent with binding experi-
ments that suggest short oligonucleotides are bound by
Cdc13(DBD) with a high nanomolar Kd (J.N.R. and
D.S.W., unpublished results). Gel shift analyses support
this being a second binding event and not simply reposi-
tioning of Cdc13(DBD) on the DNA (J.N.R. and D.S.W.,
unpublished results).
Full-length Cdc13p showed binding similar to
Cdc13(DBD) on TEL
 –GG and TEL
 –GTGGG but,
even at concentrations below the level required for binding
all of the DNA (as judged by intensity of the ‘totally
digested’ signal in Figure 5b), Cdc13p protected the 30
terminus of TEL
 –TGTGGG and longer oligonucleotides
(Figure 5b). The 30 protection by Cdc13p is not due to a
bona ﬁde ‘end-binding’ preference by the full-length pro-
tein, but rather is more likely caused by a slight alteration
in the sequence and length preferences for binding by full-
length Cdc13p compared to its DBD alone (J.N.R. and
D.S.W. unpublished results).
With well-characterized tail structures in hand, we
tested telomerase activity on these primers in the presence
and absence of bound Cdc13p and Cdc13(DBD). In their
absence, telomerase was active on all TEL
 -based primers,
though lower activity was seen with TEL
 –GG given its
limited ability to anneal to the telomerase RNA template
(Figure 5b and Supplementary Figure 1). We found that
both Cdc13p and Cdc13(DBD) inhibited telomerase
action on every primer tested. The DBD and full-length
Cdc13p inhibited telomerase action similarly, despite the
diﬀerences in binding to these telomeric substrates
(Figure 5c). Residual telomerase activity correlated well
with the fraction of unbound primer present (as measured
by the fraction of primer fully digested in our SVP assay;
Supplementary Figure 2 online), suggesting the bound
state is fully inhibitory. In the presence of a short, acces-
sible 5-nt tail, no telomerase activity was observed.
Cdc13p and DBD remain 50-localized in this condition,
suggesting that an available 5-nt protruding end is too
short to support telomerase activity. With the 7-nt tail
–GTGTGGG, Cdc13(DBD) bound the 50-end preferen-
tially, whereas Cdc13p bound the 30-end of this DNA,
yet telomerase was similarly inhibited in both cases.
While 30-end-binding by Cdc13p is likely to physically
occlude telomerase access, the inhibition observed in the
presence of Cdc13(DBD) suggests that even a tail of seven
accessible nucleotides is insuﬃcient to support telomerase
action. Telomerase was also fully inhibited when a 9-nt tail
was appended to TEL
 , although both Cdc13p and DBD
are bound relatively closer to the 30-end (cf. Figure 5b
lanes 27–29 with lanes 35–37), inhibiting telomerase in a
similar manner (cf. Figure 5c lanes 23–25 with 30–32).
Thus, our CoNuTe experiments with TEL
 -based pri-
mers show that Cdc13p and its DBD alone each potently
inhibit telomerase even when bound rather distant from
the 30 terminus. Furthermore, these results show that a
7-nt 30 tail beyond a DBD binding site is still too short
for productive telomerase access to DNA. However,
establishing the tail length that would allow for recovery
of telomerase activity to protein-bound primers is not pos-
sible with the TEL
  design as longer telomeric tails neces-
sarily create a second protein binding site, as observed
with a 9-nt tail. To further explore the minimal 30 tail
length required for telomerase access we employed a dif-
ferent approach to constraining the protein binding regis-
ter, as follows.
Action atadistance
Since Cdc13(DBD) and Cdc13p bind the 30-end of TEL
 -
based oligonucleotides with long extensions, we designed
an alternate set of primers for determining the minimal
length of DNA required to recover telomerase activity
on Cdc13p/DBD-bound primers. In this design, a canoni-
cal 11-nt Cdc13p/DBD binding TEL site at the 50-end is
separated from a robust telomerase-annealing substrate
sequence –TGTGGG at the 30-end using a non-telomeric
spacing sequence (tracts of deoxyadenosines). Control
experiments showed that a TGTGGG hexamer was read-
ily extended by telomerase but was not bound tightly by
Cdc13p (data not shown). This approach diﬀers from the
TEL
 -based oligonucleotide series, shown in Figure 5,
in three key ways: (i) the region complementary to
TLC1 (–TGTGGG) is invariant at the 30 end of all primers
Nucleic Acids Research,2009, Vol. 37,No. 2 361Figure 5. A coordinated assay reveals that Cdc13p and its DBD inhibit telomerase similarly via distinct DNA interactions. (a) CoNuTe
assay scheme used to generate data in b and c. (b) SVP assay shows that Cdc13(DBD) (D) preferentially protects TEL
  even in the context of
long 30 telomeric appendages, while Cdc13p (C) protects the 30 region of substrates with >6-nt tails. Oligonucleotides tested are shown: TEL
  region
is boxed and vertical lines indicate complementarity to TLC1 RNA shown above, while gray arrows indicate the 7 TLC1-endoded nucleotides
predicted to be added to each by telomerase (results for which are shown in c). SVP results are shown below. V-shaped arrowhead indicates
completely undigested 50-end labeled primer. TEL
 , region of gel with SVP products 11 nucleotides or shorter. Arrowhead indicates full-length 50-end
labeled oligonucleotide. Totally digested, DNA not protected by binding to DBD or Cdc13p; serves as an indicator for fraction complex formation.
Concentrations of Cdc13(DBD) were 0.15mM, 0.3mM and 0.6mM and for Cdc13p were 0.3mM, 0.6mM and 1.2mM. (c) Telomerase is consistently
inhibited by the DBD and Cdc13p bound to TEL
 -based oligonucleotides containing 2–9-nt appendages. Pre-labeled 50-end-labeled primers, included
in the reaction for the SVP experiment shown in (b), are indicated for the shortest primer and serves as a recovery and loading control for telomerase
activity assays. The +1 and +7 telomerase products are indicated as in Figures 1 and 2 (gray arrows in b). See legend b for concentrations of DBD
and Cdc13p.
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within the telomerase active site (Figure 6a); (ii) there is no
theoretical limit to the length of spacer nucleotides that
can be inserted between the 30-end and the Cdc13p/DBD
binding site since deoxyadenosines do not create a new
DBD or Cdc13p site, and (iii) as a result, the high-aﬃnity
TEL sequence, as opposed to TEL
 , can be used.
Using this series of primers in the CoNuTe assay,
we examined eﬀects of DBD and Cdc13p. As anticipated,
both proteins bound preferentially to the 50 TEL region
based on SVP protection (Figure 6a). Cdc13(DBD) inhib-
ited telomerase action substantially, though not com-
pletely (13 3% residual activity), on all of the TEL–an–
TGTGGG (n=5, 8, 11) primers (Figure 6b), even when
the telomerase-annealing site was as far as 11-nt away from
the DBD consensus binding site. SVP analysis showed that
Cdc13(DBD) did not extensively protect the 30-end at con-
centrations that were largely inhibitory. Thus, by binding
to TEL at the 50-end, Cdc13(DBD) is eﬀectively inhibiting
telomerase activity from 5–11 single-stranded nucleotides
away, producing an inhibitory eﬀect when bound at a sig-
niﬁcant distance from the telomerase annealing site, which
we refer to as action at a distance.
Cdc13p was an even more potent inhibitor of telomer-
ase than the DBD for TEL–an–TGTGGG (n=5,8,11)
substrates, leading to complete loss of telomerase action
on all primers tested (Figure 6b, lanes 7, 14, and 21).
We propose that this inhibition originates from a com-
bination of action at a distance as well as more direct
inhibition due to a concentration-dependent mode of 30
end binding. At higher protein concentrations, Cdc13p
shifts 30 in these telomerase-refractory complexes
(Figure 6a, lanes 8, 16 and 24). Protection, however, is
not observed on a control primer a11–a11–TGTGGG
(Figure 6a, lanes 30–32) lacking the TEL binding
sequence, suggesting the hexamer telomeric portion does
not support stable Cdc13p association. The concentration-
dependence of this 30 shift in SVP protection suggests
that once Cdc13p is bound to the 50 TEL sequence of
these oligonucleotides, it can facilitate the addition of a
second protein. We looked for evidence of a second bind-
ing event by gel shift and, although we readily observe the
initial binding of Cdc13p onto these primers, a higher
mobility band was not observed at high Cdc13p protein
concentrations (data not shown). This may be because this
secondary binding interaction is rather weak (in the micro-
molar range) and is not stable during electrophoresis.
Close comparison of data from the control experiments
provides some insights into the mechanism of the inhi-
bition at a distance observed for both the DBD and
Cdc13p. We observe that the activity of telomerase on
TEL–a11–TGTGGG is 47 16% higher than the same
oligonucleotide with no TEL sequence at the 50-end (a11–
a11–TGTGGG; Figure 6b, lane 15 versus 22). This sug-
gests that the TEL sequence, even 11nt away from –
TGTGGG 30-end, has the ability to enhance telomerase
activity. When Cdc13(DBD) binds to TEL, it likely
restricts the contribution of TEL to telomerase activity,
providing a potent alternative mechanism of inhibition.
For all of the control primers with no TEL sequence
at the 50-end (a11–a11–TGTGGG, a11–TGTGGG and
a5–TGTGGG), DBD could partly inhibit telomerase at
the highest protein concentration tested in the CoNuTe
experiment. SVP results from the CoNuTe assays also
show some binding to the tract of deoxyadenosines by
DBD (Figure 6a, lanes 27–29), which is not observed
for Cdc13p at these concentrations, probably due to the
intrinsic aﬃnity diﬀerences between full-length and
the DBD which carry over to nonspeciﬁc interactions.
The Kd for DBD interaction with hexamer TGTGGG is
very close to the working concentration of primer in the
CoNuTe reactions (300nM) (data not shown). Thus,
we conclude that the DBD is inhibiting telomerase
through a combination of low-aﬃnity interactions for
these primers.
DISCUSSION
Studies in various organisms have shown that the primary
chromosome end-binding proteins play two direct roles in
regulating genome stability: (i) protecting the chromo-
some end, which otherwise would elicit a DNA-damage
response, and (ii) regulating telomerase access to the 30
terminus, thereby controlling chromosome end synthesis
(31,32,35,56,57). Here we have shown that Cdc13p, as well
as its DNA-binding domain alone, block telomerase
access, thus inhibiting its action. This result is reminiscent
of studies with human POT1 and ciliate telomere end
binding protein (TEBPa/b), which have also been shown
to inhibit telomerase in vitro (34,35,56). However, Cdc13p
inhibition diﬀers from these cases in multiple ways, as
discussed below.
Cdc13pcan inhibit telomerase by three different modes,
whereas DBD exhibits two
Our data reveal three related mechanisms of Cdc13p inhi-
bition of telomerase (Figure 7). The ﬁrst of the inhibitory
modes occurs when the telomerase active site is simply
blocked from productively accessing the 30-end (‘complete
occlusion’) (Figure 7b). This activity is readily explained in
context of the structure of Cdc13(DBD) bound to TEL
sequence (26): the bases are all buried in a highly aromatic
protein DNA interface, and DNA hybridization with the
telomerase RNP could only occur upon gross structural
rearrangement. This scenario applies to most of the inhi-
bitory situations we have described herein, such as with
primer TP1 in Figures 1 and 2, using the DBD and
Cdc13p, respectively. This occlusion mechanism is sup-
ported by the observation that the DNA-binding defective
Y522A point-mutant of the Cdc13(DBD) does not inhibit
telomerase activity (Figure 1d). We also observed that
residual telomerase activity is proportional to amount of
unbound primer when it is available in excess over protein
(Supplementary Figure 2). Furthermore, the fact that
more Cdc13(DBD) and Cdc13p are required to inhibit
telomerase action as primer concentration is increased
supports a straightforward model of competitive binding
of protein to DNA that regulates telomerase action.
The second mode of observed inhibition unveils an
apparent sensitivity of yeast telomerase to Cdc13p or
DBD positioned far upstream from the 30-end on long
Nucleic Acids Research,2009, Vol. 37,No. 2 363Figure 6. ‘Spacer’ tracts of deoxyadenosines separate the DBD- and Cdc13p-binding site (TEL) and a telomerase-extendible 30-end, providing
further insight into Cdc13p inhibitory mechanisms. (a) Cdc13p, like DBD, preferentially binds TEL, but it also loads towards the 30-end at
higher protein:DNA stoichiometry. SVP data are shown from CoNuTe assay [telomerase results from this CoNuTe experiment are shown
in (b)]. Protein concentrations used here and in CoNuTe telomerase assay below are the same as in Figure 5. (b) Both Cdc13p and its DBD
inhibit telomerase on TEL-An–TGTGGG oligonucleotides with 5, 8 or 11-nt spacers. See data in (a) for SVP results from this CoNuTe experiment,
legend of Figure 5a for concentrations of DBD and Cdc13p. Primers a11-a11-TGTGGG, a11-TGTGGG and a5-TGTGGG serve as controls.
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inhibition is less eﬃcient than the direct occlusion inhibi-
tion, but nevertheless it represents a novel activity that
provides insights into the mechanism of telomerase
action and its regulation. Telomerase activity, which is
enhanced by presence of 50 telomeric sequence, is recipro-
cally reduced by DBD and Cdc13p when they are bound
to this region of these primers (Figure 6). With only six
telomeric nucleotides at the 30-end of these oligonucleo-
tides, this 50 TEL telomerase interface is particularly
important for productive substrate-enzyme interaction.
Binding of TEL by Cdc13(DBD) then blocks this activ-
ity-stimulating interaction, reducing telomerase activity
(Figure 7c). Since this region of the primer almost cer-
tainly does not directly anneal to telomerase RNA, the
inhibition by distally 50-bound Cdc13(DBD) must be
mediated through alternative interactions. One possibility
is that binding to the 50-end of the primers inhibits the
ability of the primer to interact with the telomerase
‘anchor site’ (58), which has been reported to positively
and negatively aﬀect yeast telomerase activity (59). The
anchor site of yeast telomerase may be similar to that of
other telomerases, possessing multiple sites that bind
DNA based on its speciﬁc length and sequence (60,61).
The third mode of telomerase inhibition is exhibited by
Cdc13p but not its DBD alone, implicating other domains
of the protein in mediating this activity. The SVP protec-
tion results for Cdc13p from the CoNuTe assay shown in
Figure 6a demonstrate a pattern of increased 30 protection
at the highest Cdc13p concentrations. Furthermore, com-
plete telomerase inhibition does not appear until there is
this 30 shift in SVP protection pattern (Figure 6). Thus, it
seems that after Cdc13p initially binds to the 50 region of
these oligonucleotides, it facilitates additional 30 DNA
protection from nuclease and also telomerase action in a
Cdc13p concentration-dependent manner. These results
suggest an additional mode of inhibition, which we refer
to as facilitated occlusion (Figure 7d). How Cdc13p
protects additional 30 sequences once bound to TEL
and whether this eﬀect is speciﬁc to these particular
substrates is not yet entirely clear. It may involve binding
of a second protein, but we have not directly demon-
strated this.
Telomerase regulation by themajor telomere end-binding
proteins: yeast Cdc13p inperspective
Cdc13p and human POT1 both inhibit telomerase activity
in vitro by binding DNA and occluding access of telomer-
ase to its substrate [(35) and this work]. Human telomer-
ase can access hPOT1 DNA substrates productively when
6 nt or more are protruding past the protein binding site
at the 30-end (35). This activity is exhibited by both the
full-length POT1 protein and its DNA-binding domain.
However, in budding yeast the telomeric ssDNA-binding
protein serves additional functions. A 7-nt protruding tail
beyond the bound Cdc13(DBD) is a relatively nonproduc-
tive substrate for yeast telomerase. In fact, even when
Cdc13p or its DBD alone were bound as far away as
17nt from the 30-end of a telomerase substrate, telomerase
activity was blocked. These data suggest that the role of
Cdc13p in regulating telomerase activity is more multi-
faceted than that exhibited by hPOT1.
In vivo, Cdc13p is both a positive and negative regu-
lator of telomere length (23,62,63). A truncated version
of Cdc13p lacking the C-terminal domain, which follows
the DBD, leads to elongated telomeres (33). This cdc13-5
allele may behave like the DBD alone in vitro, because the
N-terminus of Cdc13p has not been implicated in DNA
binding, but rather in protein–protein interactions to
recruit the telomerase holoenzyme to telomeres (63).
With the development of quantitative assays and a
Figure 7. Models for the relationship between telomeric DNA binding
and telomerase inhibition by Cdc13p. (a) In the absence of any telomere-
binding protein, telomerase binds to its substrate and readily extends it
via reverse transcription of its RNA template. (b) Complete occlusion
model for inhibition of telomerase. The DNA-binding domain as well
as full-length Cdc13p are capable of occluding telomerase access to the
30-end of its substrate, even when additional 30 nucleotides protrude
beyond the Cdc13 DNA interaction interface. (c) Action at a distance
inhibition. Although part of telomerase interaction with DNA is blocked
by DBD or Cdc13p, some telomerase activity is achieved, presumably via
interaction of the catalytic site and the very 30-end. (d) Facilitated occlu-
sion model. Cdc13p binds secondarily towards the 30-end of the DNA
primer in a concentration-dependent manner, leading to more potent
inhibition. This is stepwise, eﬀectively inhibiting ﬁrst as indicated in c
(action at a distance) and then, additionally, as shown in b (complete
occlusion), when Cdc13p loads also on the 30-end, facilitated by ﬁrst
loading at a more 50 position.
Nucleic Acids Research,2009, Vol. 37,No. 2 365reconstituted minimal system, we have a better under-
standing of the role of Cdc13p on telomerase function.
Our inability to ﬁnd a primer that, upon binding of
Cdc13p, is a robust telomerase substrate suggests that
the positive regulation role of Cdc13p is mediated in con-
junction with other telomere factors. Approximately 273
genes have been shown to have a direct or indirect role in
mediating telomere length (64,65). Many of these elicit
their eﬀects indirectly, but some are direct regulators.
Est1p, a component of telomerase that interacts with
Cdc13p to recruit telomerase to telomeres, is a prime can-
didate to overcome the basal repressive activity of Cdc13p.
Like Est1p, Est3p is telomerase-associated and essential
for telomerase function in vivo (53,66). Stn1p and Ten1p
also interact with Cdc13p and display telomere length
phenotypes (62). The in vitro system presented here will
be a powerful tool to dissect the role of telomere-asso-
ciated factors in mediating telomere length homeostasis.
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